Sinovac Life Sciences Co., Ltd.

This study is testing a new 24-valent pneumococcal conjugate vaccine (PCV24) in healthy children aged 2 to 23 months. The main goal is to check if the vaccine is safe and if it triggers a good immune response to protect against pneumococcal diseases like pneumonia and meningitis.…

This study is testing a new version of a vaccine designed to protect infants and young children from serious pneumococcal infections, like some types of pneumonia and meningitis. It will enroll 3080 healthy children, from 6 weeks to under 6 years old, to compare the safety and im…

This study is testing a new vaccine designed to protect children from serious infections like pneumonia and meningitis. It will compare the new vaccine's safety and ability to trigger an immune response against an existing, approved vaccine. The trial will involve 420 healthy chi…